Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania: Results from a randomized controlled trial

Madhav A. Namjoshi, Gopalan Rajamannar, Thomas Jacobs, Todd M. Sanger, Richard Risser, Mauricio F. Tohen, Alan Breier, Paul E. Keck

Research output: Contribution to journalArticle

49 Scopus citations


Introduction: The objectives of this study were to determine the economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in patients diagnosed with mania. Methods: Patients with a diagnosis of bipolar I disorder with manic or mixed episodes were enrolled in a randomized controlled trial. The study design comprised a 3-week acute phase followed by a 49-week open label extension. In the open label extension, the use of lithium and fluoxetine was permitted for patients who experienced breakthrough symptoms. Clinical, economic, and quality-of-life outcomes of treatment were assessed. Results: During the acute phase, olanzapine patients experienced a statistically significant greater mean improvement from baseline on the Y-MRS total score compared to the placebo patients. In the open label extension, patients experienced a statistically significant mean change of 11.8 units on the Y-MRS from the end of the acute phase. When compared to costs incurred in the previous 12 months of therapy, patients experienced savings of almost $ 900 per month during the 49 weeks of olanzapine therapy. These cost savings were largely driven by reductions in in-patient costs during the open label extension. Health-related quality of life improvements measured by the SF-36 were seen on several dimensions both in the 3-week acute phase as well as in the 49-week open label extension. Conclusion: From a clinical, economic, and quality-of-life outcomes standpoint, olanzapine had a significant impact in the treatment of mania, and could be considered a cost-effective treatment option for use in this population if these findings are extrapolated to non-clinical trial populations.

Original languageEnglish (US)
Pages (from-to)109-118
Number of pages10
JournalJournal of Affective Disorders
Issue number1-3
StatePublished - Jul 15 2002



  • Direct medical costs
  • Mania
  • Olanzapine
  • Quality of life

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychiatry and Mental health

Cite this